Forbes1y
Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita
Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. Yesterday, Amgen announced that it would launch the U.S.’s first marketed ...
Medscape2d
B-Cell Depleting Drug Shines in IgG4-Related Disease
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
STAT5d
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
STAT6d
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
Nasdaq6d
What's Behind The 50% Rise In Amgen Stock?
Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone ...
Is Amgen Stock a Buy?
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.
Forbes6d
What’s Happening With Amgen Stock?
Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone ...